Form 4: Dyne Therapeutics Director Jason Rhodes Reports Stock Sales Under 10b5-1 Plans

Director Jason Rhodes reported sales of Dyne Therapeutics (DYN) common stock on March 1, 2024, executed under pre-arranged Rule 10b5-1 trading plans.

Summary

• Jason Rhodes, a director of Dyne Therapeutics, reported the sale of common stock on March 1, 2024.
• The sales were executed under Rule 10b5-1 trading plans adopted by Atlas Venture Opportunity Fund I, L.P. and Atlas Venture Opportunity Fund II, L.P. on January 10, 2024.
• 29,435 shares were sold at a weighted average price of $30.05.
• 17,099 shares were sold at a weighted average price of $30.05.
• The shares are indirectly held by Atlas Venture Opportunity Fund I, L.P., Atlas Venture Opportunity Fund II, L.P., and Atlas Venture Fund XI, L.P.
• Rhodes disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. It is neutral in tone and doesn't inherently suggest positive or negative sentiment about the company's prospects.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of trading on material non-public information. The filing provides transparency into these transactions.

Stakeholder Impact

• The stock sale by a director could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates